 Elizabeth Frazier
Concepts (190)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 25 | 2017 | 344 | 2.980 |
Why?
| | Graft Rejection | 6 | 2015 | 168 | 1.100 |
Why?
| | Heart Failure | 8 | 2017 | 506 | 0.770 |
Why?
| | Heart-Assist Devices | 9 | 2016 | 150 | 0.750 |
Why?
| | Extracorporeal Membrane Oxygenation | 7 | 2016 | 289 | 0.690 |
Why?
| | Cardiomyopathy, Dilated | 3 | 2015 | 39 | 0.630 |
Why?
| | Down Syndrome | 1 | 2015 | 89 | 0.480 |
Why?
| | Child, Preschool | 22 | 2017 | 3883 | 0.470 |
Why?
| | Child | 28 | 2020 | 6851 | 0.460 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 185 | 0.450 |
Why?
| | Azygos Vein | 2 | 2013 | 11 | 0.420 |
Why?
| | Infant | 21 | 2017 | 3563 | 0.410 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 29 | 0.400 |
Why?
| | Peptide Fragments | 1 | 2012 | 213 | 0.370 |
Why?
| | Heart Defects, Congenital | 4 | 2017 | 585 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 990 | 0.330 |
Why?
| | Tissue Donors | 2 | 2012 | 113 | 0.310 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2007 | 11 | 0.300 |
Why?
| | Retrospective Studies | 18 | 2017 | 6134 | 0.300 |
Why?
| | Bone Density | 1 | 2009 | 379 | 0.290 |
Why?
| | HLA Antigens | 3 | 2013 | 53 | 0.280 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2007 | 119 | 0.270 |
Why?
| | Renal Insufficiency | 1 | 2007 | 109 | 0.270 |
Why?
| | Humans | 33 | 2020 | 50208 | 0.240 |
Why?
| | Stents | 1 | 2007 | 343 | 0.240 |
Why?
| | Female | 23 | 2017 | 26635 | 0.230 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2004 | 45 | 0.230 |
Why?
| | Tissue and Organ Procurement | 1 | 2004 | 41 | 0.230 |
Why?
| | Adolescent | 16 | 2016 | 6390 | 0.220 |
Why?
| | Male | 23 | 2017 | 25399 | 0.220 |
Why?
| | Isoantibodies | 2 | 2013 | 25 | 0.210 |
Why?
| | Infant, Newborn | 7 | 2016 | 2766 | 0.200 |
Why?
| | Hospice Care | 1 | 2020 | 26 | 0.180 |
Why?
| | Terminal Care | 1 | 2020 | 46 | 0.170 |
Why?
| | Risk Factors | 7 | 2016 | 3629 | 0.170 |
Why?
| | Home Care Services | 1 | 2020 | 73 | 0.160 |
Why?
| | Heart Diseases | 3 | 2012 | 211 | 0.160 |
Why?
| | Waiting Lists | 2 | 2016 | 54 | 0.150 |
Why?
| | Treatment Outcome | 11 | 2015 | 5155 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 95 | 0.140 |
Why?
| | Odds Ratio | 3 | 2012 | 546 | 0.130 |
Why?
| | Time Factors | 7 | 2015 | 2922 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2012 | 2190 | 0.130 |
Why?
| | Age of Onset | 1 | 2015 | 107 | 0.130 |
Why?
| | Respiration, Artificial | 2 | 2015 | 274 | 0.120 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 51 | 0.120 |
Why?
| | Vena Cava, Inferior | 1 | 2013 | 79 | 0.110 |
Why?
| | Cytoplasmic Granules | 1 | 2012 | 25 | 0.110 |
Why?
| | Ventricular Function | 1 | 2012 | 18 | 0.110 |
Why?
| | Parvoviridae Infections | 1 | 2012 | 20 | 0.100 |
Why?
| | Parvovirus B19, Human | 1 | 2012 | 17 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2012 | 21 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 86 | 0.100 |
Why?
| | Logistic Models | 2 | 2012 | 889 | 0.100 |
Why?
| | Echocardiography, Transesophageal | 1 | 2012 | 60 | 0.100 |
Why?
| | Arkansas | 5 | 2012 | 1985 | 0.100 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 75 | 0.100 |
Why?
| | Myocarditis | 1 | 2012 | 43 | 0.100 |
Why?
| | DNA, Viral | 1 | 2012 | 134 | 0.100 |
Why?
| | Ductus Arteriosus | 1 | 2011 | 11 | 0.100 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 171 | 0.100 |
Why?
| | Catheters | 1 | 2011 | 31 | 0.100 |
Why?
| | Cystatin C | 1 | 2011 | 9 | 0.100 |
Why?
| | Lipocalins | 1 | 2011 | 13 | 0.100 |
Why?
| | Cardiac Catheterization | 2 | 2010 | 214 | 0.100 |
Why?
| | Acute-Phase Proteins | 1 | 2011 | 24 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 104 | 0.090 |
Why?
| | Boronic Acids | 1 | 2012 | 182 | 0.090 |
Why?
| | Pyrazines | 1 | 2012 | 187 | 0.090 |
Why?
| | Heparin | 2 | 2008 | 92 | 0.090 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 65 | 0.090 |
Why?
| | Carrier Proteins | 1 | 2012 | 306 | 0.090 |
Why?
| | Catheterization | 1 | 2011 | 100 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 149 | 0.090 |
Why?
| | Echocardiography, Doppler | 1 | 2010 | 52 | 0.090 |
Why?
| | Cardiology | 1 | 2011 | 87 | 0.090 |
Why?
| | Fontan Procedure | 1 | 2010 | 62 | 0.090 |
Why?
| | Norwood Procedures | 1 | 2010 | 56 | 0.090 |
Why?
| | Oxygen | 1 | 2012 | 325 | 0.080 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2010 | 93 | 0.080 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 153 | 0.080 |
Why?
| | Anticoagulants | 2 | 2008 | 253 | 0.080 |
Why?
| | Pipecolic Acids | 1 | 2008 | 7 | 0.080 |
Why?
| | Fractures, Bone | 1 | 2009 | 106 | 0.080 |
Why?
| | Body Weight | 1 | 2010 | 512 | 0.080 |
Why?
| | Transplantation | 1 | 2008 | 14 | 0.080 |
Why?
| | Echocardiography | 1 | 2011 | 375 | 0.080 |
Why?
| | Heart Septum | 1 | 2008 | 24 | 0.080 |
Why?
| | Tricuspid Valve | 1 | 2008 | 22 | 0.080 |
Why?
| | Drug-Eluting Stents | 1 | 2008 | 93 | 0.080 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 12 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 19 | 0.070 |
Why?
| | Coronary Disease | 1 | 2008 | 152 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2008 | 84 | 0.070 |
Why?
| | Angiography | 1 | 2007 | 130 | 0.070 |
Why?
| | Prosthesis Design | 1 | 2008 | 237 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 137 | 0.070 |
Why?
| | Kidney | 1 | 2011 | 672 | 0.070 |
Why?
| | Oximetry | 1 | 2007 | 67 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2007 | 188 | 0.070 |
Why?
| | Cerebrovascular Circulation | 1 | 2007 | 132 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 466 | 0.070 |
Why?
| | Cerebral Cortex | 1 | 2007 | 200 | 0.060 |
Why?
| | Hospitals, Pediatric | 1 | 2006 | 236 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2014 | 1126 | 0.060 |
Why?
| | Palliative Care | 2 | 2020 | 186 | 0.060 |
Why?
| | Prevalence | 1 | 2007 | 951 | 0.060 |
Why?
| | Reoperation | 2 | 2014 | 454 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 905 | 0.050 |
Why?
| | Terminally Ill | 1 | 2020 | 13 | 0.040 |
Why?
| | Young Adult | 1 | 2009 | 3981 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 666 | 0.040 |
Why?
| | Graft Survival | 2 | 2012 | 150 | 0.040 |
Why?
| | Critical Care | 1 | 2020 | 213 | 0.040 |
Why?
| | Warfarin | 2 | 2008 | 86 | 0.040 |
Why?
| | Prospective Studies | 3 | 2010 | 2379 | 0.040 |
Why?
| | Length of Stay | 2 | 2010 | 621 | 0.030 |
Why?
| | Child Welfare | 2 | 2008 | 54 | 0.030 |
Why?
| | Age Factors | 2 | 2010 | 1092 | 0.030 |
Why?
| | Mitral Valve Insufficiency | 1 | 2015 | 45 | 0.030 |
Why?
| | Sternotomy | 1 | 2014 | 7 | 0.030 |
Why?
| | Blood Coagulation Disorders | 1 | 2014 | 38 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2013 | 59 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 657 | 0.030 |
Why?
| | Serine | 1 | 2012 | 37 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 82 | 0.030 |
Why?
| | RNA Helicases | 1 | 2012 | 29 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 193 | 0.030 |
Why?
| | Texas | 1 | 2012 | 139 | 0.030 |
Why?
| | HeLa Cells | 1 | 2012 | 260 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 278 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2012 | 47 | 0.020 |
Why?
| | Morbidity | 1 | 2012 | 134 | 0.020 |
Why?
| | Patient Safety | 1 | 2012 | 102 | 0.020 |
Why?
| | Pulmonary Valve | 1 | 2012 | 45 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2012 | 170 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 195 | 0.020 |
Why?
| | Tetralogy of Fallot | 1 | 2012 | 80 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2011 | 41 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 534 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 454 | 0.020 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2010 | 8 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2011 | 111 | 0.020 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2010 | 22 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2010 | 16 | 0.020 |
Why?
| | DNA Helicases | 1 | 2012 | 144 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2010 | 27 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 262 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2010 | 38 | 0.020 |
Why?
| | Mitral Valve | 1 | 2010 | 49 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2012 | 150 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 232 | 0.020 |
Why?
| | Survival Rate | 1 | 2012 | 901 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 165 | 0.020 |
Why?
| | Heart | 1 | 2012 | 331 | 0.020 |
Why?
| | Recovery of Function | 1 | 2010 | 187 | 0.020 |
Why?
| | Myocardium | 1 | 2012 | 438 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 564 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 200 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 1422 | 0.020 |
Why?
| | Dipyridamole | 1 | 2008 | 9 | 0.020 |
Why?
| | Heparin Antagonists | 1 | 2008 | 7 | 0.020 |
Why?
| | Protamines | 1 | 2008 | 8 | 0.020 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2008 | 20 | 0.020 |
Why?
| | Antithrombin III | 1 | 2008 | 12 | 0.020 |
Why?
| | Thrombin | 1 | 2008 | 38 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2008 | 28 | 0.020 |
Why?
| | Biopsy | 1 | 2010 | 590 | 0.020 |
Why?
| | North America | 1 | 2008 | 64 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2008 | 213 | 0.020 |
Why?
| | Drug Interactions | 1 | 2008 | 208 | 0.020 |
Why?
| | Adult | 3 | 2012 | 13324 | 0.020 |
Why?
| | Postoperative Care | 1 | 2008 | 102 | 0.020 |
Why?
| | Sulfonamides | 1 | 2008 | 128 | 0.020 |
Why?
| | Patient Compliance | 1 | 2008 | 230 | 0.020 |
Why?
| | Aspirin | 1 | 2008 | 114 | 0.020 |
Why?
| | Prognosis | 1 | 2012 | 1954 | 0.020 |
Why?
| | Arginine | 1 | 2008 | 179 | 0.020 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2007 | 53 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2008 | 355 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2008 | 174 | 0.020 |
Why?
| | Postoperative Period | 1 | 2007 | 168 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 465 | 0.020 |
Why?
| | Ultrasonography | 1 | 2008 | 437 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 1622 | 0.020 |
Why?
| | Infant Welfare | 1 | 2003 | 5 | 0.010 |
Why?
| | Cardiomyopathies | 1 | 2003 | 116 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2003 | 251 | 0.010 |
Why?
| | Aged | 1 | 2012 | 9405 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2003 | 996 | 0.010 |
Why?
|
|
Frazier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|